Related Experiment Video
Updated: Jun 8, 2026

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
Published on: February 23, 2024
Nanochemoprevention: sustained release of bioactive food components for cancer prevention
Imtiaz A Siddiqui1, Vaqar M Adhami, Nihal Ahmad
1Department of Dermatology, University of Wisconsin, Madison, Wisconsin 53706, USA.
Abstract:
Chemoprevention, especially through the use of naturally occurring phytochemicals capable of impeding the process of carcinogenesis at one or more steps, is an ideal approach for cancer management. Despite accomplished outcomes in preclinical settings, its applicability to humans has met with limited success for many reasons including inefficient systemic delivery and bioavailability of promising chemopreventive agents. We have recently introduced a novel concept of "nanochemoprevention" that utilizes nanotechnology for enhancing the outcome of chemoprevention (Cancer Res 69, 1712-1716, 2009). To establish the usefulness of nanochemoprevention in cancer management, we studied the efficacy of a well identified chemopreventive agent epigallocatechin-3-gallate (EGCG) encapsulated in polylactic acid (PLA) and polyethylene glycol (PEG) nanoparticles (hereafter referred to as nano-EGCG) in preclinical settings. Nano-EGCG was found to retain its biological effectiveness, with over 10-fold dose advantage compared to nonencapsulated EGCG for exerting its cell growth inhibition, proapoptotic, and angiogenic inhibitory effects. Nano-EGCG was also observed to be effective in inhibiting tumor cell growth in athymic nude mice, with over 10-fold dose advantage compared to nonencapsulated EGCG. The rate of degradation of nonencapsulated EGCG was rapid, with a complete degradation within 4 h, whereas nano-EGCG had a significantly longer half-life. This study provides a foundation for the use of nanoparticle-mediated delivery of natural products to enhance the bioavailability of active agents for their enhanced effective and chemopreventive potential. In doing this, it is hoped that perceived toxicity concerns associated with prolonged use of agents could also be minimized. Oral consumption is the most desirable and acceptable form of delivery of chemopreventive agents. One disadvantage of using PLA-PEG nanoparticles is its unstable nature in acidic environment; and therefore, it is not recommended for oral consumption. To overcome this obstacle, it will be important to develop nanoparticles encapsulating phytochemicals that are suitable for oral consumption.
Insights
Nanoparticle encapsulation of epigallocatechin-3-gallate (EGCG) enhances its cancer-fighting properties and bioavailability. This nanochemoprevention approach shows promise for improved cancer management, though oral delivery requires further development.
Area of Science:
- Nanotechnology
- Phytochemistry
- Cancer Research
Background:
- Chemoprevention using natural phytochemicals is a promising cancer management strategy.
- Limited human success is often due to poor systemic delivery and bioavailability of agents.
- Nanochemoprevention utilizes nanotechnology to improve chemopreventive agent efficacy.
Purpose of the Study:
- To evaluate the efficacy of epigallocatechin-3-gallate (EGCG) encapsulated in polylactic acid (PLA) and polyethylene glycol (PEG) nanoparticles (nano-EGCG).
- To establish the potential of nanochemoprevention for enhanced cancer management.
- To assess the impact of nanoparticle encapsulation on EGCG's bioavailability and degradation rate.
Main Methods:
- Encapsulation of EGCG in PLA-PEG nanoparticles to create nano-EGCG.
- Preclinical testing of nano-EGCG for biological effectiveness, including cell growth inhibition, apoptosis, and angiogenesis inhibition.
- In vivo efficacy studies in athymic nude mice to assess tumor growth inhibition.
- Comparison of degradation rates between nonencapsulated EGCG and nano-EGCG.
Main Results:
- Nano-EGCG demonstrated over 10-fold dose advantage compared to nonencapsulated EGCG for cellular effects.
- Nano-EGCG significantly inhibited tumor growth in mice, also with over 10-fold dose advantage.
- Nonencapsulated EGCG degraded rapidly within 4 hours, while nano-EGCG exhibited a significantly longer half-life.
- Nano-EGCG retained biological effectiveness, improving bioavailability and potentially reducing toxicity concerns.
Conclusions:
- Nanoparticle-mediated delivery of natural products like EGCG enhances bioavailability and chemopreventive potential.
- Nanochemoprevention offers a promising strategy for improving cancer management outcomes.
- Further development is needed for oral-compatible nanoparticles, as PLA-PEG nanoparticles are unstable in acidic environments.
Related Concept Videos
Cancer Prevention
Some...
Cancer Prevention
Some...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
